Over 70 Domestic and International Companies and Investment Institutions to Participate
The "2025 Pharmaceutical and Bio Investment Expo," hosted by Incheon Metropolitan City and jointly organized by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Incheon Tourism Organization, and Korea Trade-Investment Promotion Agency (KOTRA), will be held on December 2 at the Premier Ballroom of Songdo Convensia in Yeonsu-gu, Incheon.
The conference will feature pharmaceutical and bio industry experts as speakers, providing in-depth insights. In the morning session, Lee Byungun, Korea Advisor at the US investment firm Flagship Pioneering, will deliver a presentation on "Strategies for Attracting Overseas VC Investment." This will be followed by a presentation from Lee Sungho, Team Leader at KOTRA, on "Strategies for Overseas Expansion in the Pharmaceutical and Bio Industry," and Kim Deoksang, CEO of Sartorius Korea, will share "Successful Cases of Attracting Foreign Investment."
There will also be a session dedicated to sharing the roles and future growth strategies of pharmaceutical and bio companies. Kwon Kisung, Senior Executive Vice President of Celltrion, will speak on "The Role of Leading Global Corporations in the Bio Industry," while SK Bioscience will present on "Future Growth Strategies as a New Innovation Hub."
The afternoon session will address practical investment information, including "Changes in the 2026 Investment Environment and the Acceleration of Artificial Intelligence (AI) in the Pharmaceutical and Bio Industry," with presentations by Heo Hyemin, Team Leader at Kiwoom Securities, and Kwon Hyesoon, Senior Expert at Eugene Investment & Securities. Additionally, corporate representatives such as Lee Jaehyun, Director at JNPMEDI, Ha Jaeyoung, Vice President of ARIBIO, and Hong Sunghoon, Vice President of D&D Pharmatech, will share their companies' overseas technology transfer cases and global business strategies.
The event will also feature an investment and export consultation session. This one-on-one consultation will bring together over 70 companies, including 25 overseas investors and buyers and 45 domestic pharmaceutical and bio companies. The participants will focus on creating concrete business opportunities through investment attraction and product export consultations. After the conclusion of the conference and consultation session at 5 p.m., a "K-SAPCE STATION" networking event will be held to facilitate close exchanges between investors and companies.
Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, stated, "The 2025 Pharmaceutical and Bio Investment Expo will serve as a crucial opportunity to directly connect domestic and international investors with innovative companies in Songdo, where bio anchor facilities are concentrated. We will do our utmost to ensure tangible investment attraction results and further elevate the global status of Korea's pharmaceutical and bio industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
